HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions

References

• Lu L, Pan C, Li Yet al.A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology 2012;9: 104.
   PubMed Web of Science ®Google Scholar
• Xiao X, Wu L, Stantchev TSet al.Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci USA 1999;96: 7496–7501.
   PubMed Web of Science ®Google Scholar
• Lu M, Blacklow SC, Kim PS.A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2: 1075–1082.
   PubMedGoogle Scholar
• Chan DC, Kim PS.HIV entry and its inhibition. Cell 1998;93: 681–684.
   PubMed Web of Science ®Google Scholar
• Liu S, Jiang S.High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 2004;10: 1827–1843.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ma L, Jiang Set al.Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005;339: 213–225.
   PubMed Web of Science ®Google Scholar
• Orloff SL, Kennedy MS, Belperron AAet al.Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol 1993;67: 1461–1471.
   PubMed Web of Science ®Google Scholar
• Haim H, Si Z, Madani Net al.Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 2009;5: e1000360.
   PubMed Web of Science ®Google Scholar
• Li L, Shi X, Lu Qet al.Role of human CD4 D1D2 domain in HIV-1 infection. Immunol Invest 2013;42: 106–121.
   PubMed Web of Science ®Google Scholar
• Chen W, Feng Y, Gong Ret al.Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol 2011;85: 9395–9405.
   PubMed Web of Science ®Google Scholar
• Kwong PD, Wyatt R, Robinson Jet al.Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393: 648–659.
   PubMed Web of Science ®Google Scholar
• Wyatt R, Kwong PD, Desjardins Eet al.The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393: 705–711.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhu Z, Feng Yet al.Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008;105: 17121–17126.
   PubMed Web of Science ®Google Scholar
• Ying T, Chen W, Feng Yet al.Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013;288: 25154–25164.
   PubMed Web of Science ®Google Scholar
• Chen W, Feng Y, Prabakaran Pet al.Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol 2014;88: 1125–1139.
   PubMed Web of Science ®Google Scholar
• Wild CT, Shugars DC, Greenwell TKet al.Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91: 9770–9774.
   PubMed Web of Science ®Google Scholar
• Dwyer JJ, Wilson KL, Davison DKet al.Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007;104: 12772–12777.
   PubMed Web of Science ®Google Scholar
• He Y, Xiao Y, Song Het al.Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008;283: 11126–11134.
   PubMed Web of Science ®Google Scholar
• Edelhoch H.Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967;6: 1948–1954.
   PubMed Web of Science ®Google Scholar
• Eggink D, Bontjer I, Langedijk JPet al.Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol 2011;85: 10785–10797.
   PubMed Web of Science ®Google Scholar
• Yu F, Lu L, Liu Qet al.ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Biochim Biophys Acta 2014;1838: 1296–1305.
   PubMed Web of Science ®Google Scholar
• Neurath AR, Strick N, Li YYet al.Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001;1: 17.
   PubMed Web of Science ®Google Scholar
• Jiang S, Lu H, Liu Set al.N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 2004;48: 4349–4359.
   PubMed Web of Science ®Google Scholar
• Chou TC.Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58: 621–681.
   PubMed Web of Science ®Google Scholar
• Wei DG, Chiang V, Fyne Eet al.Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014;10: e1004071.
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Liu Het al.Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46: 1896–1905.
   PubMed Web of Science ®Google Scholar
• Baldwin CE, Sanders RW, Deng Yet al.Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004;78: 12428–12437.
   PubMed Web of Science ®Google Scholar
• Chong H, Yao X, Qiu Zet al.The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. J Antimicrob Chemother 2014;69: 2759–2769.
   PubMed Web of Science ®Google Scholar
• Moebius U, Clayton LK, Abraham Set al.The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J Exp Med 1992;176: 507–517.
   PubMed Web of Science ®Google Scholar
• Trkola A, Pomales AB, Yuan Het al.Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69: 6609–6617.
   PubMed Web of Science ®Google Scholar
• Dey B, Del Castillo CS, Berger EA.Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003;77: 2859–2865.
   PubMed Web of Science ®Google Scholar
• Lagenaur LA, Villarroel VA, Bundoc Vet al.sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 2010;7: 11.
   PubMed Web of Science ®Google Scholar
• Sullivan N, Sun Y, Binley Jet al.Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 1998;72: 6332–6338.
   PubMed Web of Science ®Google Scholar
• Trkola A, Ketas T, Kewalramani VNet al.Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998;72: 1876–1885.
   PubMed Web of Science ®Google Scholar
• Chen W, Xiao X, Wang Yet al.Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 2010;88: 107–115.
   PubMed Web of Science ®Google Scholar
• Chan DC, Fass D, Berger JMet al.Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89: 263–273.
   PubMed Web of Science ®Google Scholar